This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (funded, already peer-reviewed, non-eHealth) (144) Teleoncology (18) Medication Adherence (54) Pharmacology and Pharmaceutics (29) Cancer Self-Management (37) Chemotherapy and Side Effects Management (46)

Published on in Vol 10 , No 6 (2021) :June

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/30090, first published .
Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data

Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data

Optimizing Oral Targeted Anticancer Therapies Study for Patients With Solid Cancer: Protocol for a Randomized Controlled Medication Adherence Program Along With Systematic Collection and Modeling of Pharmacokinetic and Pharmacodynamic Data

Authors of this article:

Carole Bandiera 1, 2, 3 Author Orcid Image ;   Evelina Cardoso 4 Author Orcid Image ;   Isabella Locatelli 3 Author Orcid Image ;   Antonia Digklia 5 Author Orcid Image ;   Khalil Zaman 5 Author Orcid Image ;   Antonella Diciolla 5 Author Orcid Image ;   Valérie Cristina 5 Author Orcid Image ;   Athina Stravodimou 5 Author Orcid Image ;   Aedo Lopez Veronica 5 Author Orcid Image ;   Ana Dolcan 5 Author Orcid Image ;   Apostolos Sarivalasis 5 Author Orcid Image ;   Aikaterini Liapi 5 Author Orcid Image ;   Hasna Bouchaab 5 Author Orcid Image ;   Angela Orcurto 5 Author Orcid Image ;   Jennifer Dotta-Celio 3 Author Orcid Image ;   Solange Peters 5 Author Orcid Image ;   Laurent Decosterd 6 Author Orcid Image ;   Nicolas Widmer 2, 6, 7, 8 Author Orcid Image ;   Dorothea Wagner 5 Author Orcid Image ;   Chantal Csajka 2, 4, 8 Author Orcid Image ;   Marie Paule Schneider 1, 2 Author Orcid Image
Article Authors Cited by (7) Tweetations (2) Metrics

Journals

  1. Bandiera C, Locatelli I, Courlet P, Cardoso E, Zaman K, Stravodimou A, Dolcan A, Sarivalasis A, Zurcher J, Aedo-Lopez V, Dotta-Celio J, Peters S, Guidi M, Wagner A, Csajka C, Schneider M. Adherence to the CDK 4/6 Inhibitor Palbociclib and Omission of Dose Management Supported by Pharmacometric Modelling as Part of the OpTAT Study. Cancers 2023;15(1):316 View
  2. Bandiera C, Pasquier J, Locatelli I, Niquille A, Wuerzner G, Dotta-Celio J, Hachfeld A, Wandeler G, Wagner A, Csajka C, Zanchi A, Cavassini M, Schneider M. Medication Adherence Evaluated Through Electronic Monitors During the 2020 COVID-19 Pandemic Lockdown in Switzerland: A Longitudinal Analysis. Patient Preference and Adherence 2022;Volume 16:2313 View
  3. Pasquier J, Schneider M, Locatelli I. Estimation of adherence to medication treatment in presence of censoring. British Journal of Clinical Pharmacology 2022 View
  4. Papus M, Dima A, Viprey M, Schott A, Schneider M, Novais T. Motivational interviewing to support medication adherence in adults with chronic conditions: Systematic review of randomized controlled trials. Patient Education and Counseling 2022;105(11):3186 View
  5. Courlet P, Cardoso E, Bandiera C, Stravodimou A, Zurcher J, Chtioui H, Locatelli I, Decosterd L, Darnaud L, Blanchet B, Alexandre J, Wagner A, Zaman K, Schneider M, Guidi M, Csajka C. Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer. Pharmaceutics 2022;14(7):1317 View
  6. Bandiera C, Skrabal Ross X, Cardoso E, Wagner D, Csajka C, Olver I, Patterson P, Suppiah V, Gunn K, Schneider M. Interventions to support adherence to oral anticancer therapies: research challenges, lessons learned, and strategies to overcome them from Australia and Switzerland. Supportive Care in Cancer 2022;30(5):3655 View
  7. Engel-Nitz N, Johnson M, Johnson M, Cha-Silva A, Kurosky S, Liu X. Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer. Patient Preference and Adherence 2023;Volume 17:1049 View